



# Issue of Equity from exercise of Share Options

December 6, 2016 2:34 PM EST

Released : December 06, 2016 09:34

RNS Number : 0823R

MaxCyte, Inc.

06 December 2016

## **MaxCyte, Inc.**

("MaxCyte" or the "Company")

### **Issue of Equity from exercise of Share Options**

**Maryland, USA - 06 December 2016:** MaxCyte (LSE: MXCT), announces the issue and allotment of 12,805 new ordinary shares of \$0.01 each in the Company (the "New Ordinary Shares") pursuant to the exercise of share options by a certain option holder.

Application has been made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on or around 09 December 2016. The New Ordinary Shares will rank pari passu with the existing shares of the Company. Following this allotment, the total issued share capital of the Company will increase to 43,521,234 ordinary shares.

**- ENDS -**

**For further information please contact:**

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

***Nominated Adviser and Broker***

+44 (0) 20 7886 2500

**Panmure Gordon**

Freddy Crossley (Corporate Finance)

Fabien Holler

Duncan Monteith

Tom Salvesen (Corporate Broking)

***Financial PR Advisor***

+44 (0)203 709 5700

Consilium Strategic Communications

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Mary-Jane Elliott

Chris Welsh

Lindsey Neville

**About MaxCyte**

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of \$35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit <http://www.maxcyte.com/>

END

IOEEANAKEDFKFEF